Vol. 6 No. 10 (2026): October
Reimbursement Recommendations

Romosozumab (Evenity)

decorative image of the issue cover

Published October 8, 2026

Key Messages

  • On July 16, 2026, the Formulary Management Expert Committee (FMEC) deliberated on a Request for Advice for the past romosozumab reimbursement recommendation for the treatment of osteoporosis.
  • In this case, public drug plans were seeking clarification on the definition, interpretation, and/or meaning of “treatment naive” [from original source] that should be applied for reimbursement of romosozumab, as outlined in the reimbursement conditions from the Canadian Drug Expert Committee (CDEC) in 2021.
  • FMEC recommends updating the initiation condition for the reimbursement of romosozumab, such that reimbursement would no longer be contingent upon the need for a patient to be treatment naive.